KOD vs LMAT: Which Stock Is the Better Buy?
Kodiak Sciences Inc. and LeMaitre Vascular, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — KOD vs LMAT, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Kodiak Sciences Inc. (KOD) | LeMaitre Vascular, Inc. (LMAT) | |
|---|---|---|
| Market cap | $2.1B | $2.1B |
| Revenue (latest FY) | $0 | $249.60M |
| Net income (latest FY) | $-229.97M | $57.73M |
| Revenue growth (5y CAGR) | — | 14.0% |
| Net margin | — | 23.1% |
| Return on equity | -146.1% | 14.7% |
| P/E ratio | — | 34.1 |
| Dividend yield | — | 1.0% |
| Profitable years (of last 10) | 0 | 10 |
| Positive free cash flow | No | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full KOD vs LMAT breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open KOD's full financials → Open LMAT's full financials →More comparisons
Frequently asked questions
Which is bigger, KOD or LMAT?
LeMaitre Vascular, Inc. is larger by market capitalization — $2.1B versus $2.1B.
Which grows faster, KOD or LMAT?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
KOD fundamentals → · LMAT fundamentals → · All 1,500+ companies → · Free screener →